Hims & Hers shares surge 50% after Novo Nordisk ends legal feud over compounded weight loss drugs

Core Viewpoint - Novo Nordisk has resolved its legal dispute with Hims & Hers, allowing Hims to sell Novo's branded semaglutide products, leading to a significant increase in Hims' stock price and a modest rise in Novo's stock price [2]. Group 1: Legal and Business Agreement - Novo Nordisk has dropped its patent infringement lawsuit against Hims after both companies agreed on a new business model where Hims will sell Novo's branded medicines [2][5]. - Hims will no longer advertise compounded GLP-1 drugs and will reserve compounding versions only for rare cases where necessary [6]. Group 2: Market Dynamics and Product Offerings - Hims previously profited from selling copycat versions of semaglutide due to a regulatory loophole, but Novo has since resolved supply issues, allowing for the sale of its branded products [4]. - The patent for semaglutide is protected in the U.S. until 2032, indicating a long-term competitive landscape for weight-loss drugs [5]. Group 3: Demand and Future Prospects - Hims CEO Andrew Dudum noted that the demand for anti-obesity drugs is expected to accelerate with new product assortments that cater to affordability and personalization [8]. - Hims is actively seeking partnerships with biotech and large pharmaceutical companies to expand its therapy offerings [9].